Abstract
Background: The non absorbable antibiotic rifamycin SV newly formulated as modified colonic release MMX® tablets was preliminarily investigated. Methods: In a multi-centre, double-blind, double-dummy, randomised, parallelgroup study, efficacy and safety of the 200 mg tablets were investigated vs. rifaximin 200 mg tablets in infectious diarrhoea. Results: 22 rifamycin SV recipients (47.8%) were successes, whilst 24 (52.5%) discontinued. In the reference group 27 (50.9%) were successes, whilst 26 (49.1%) discontinued. The median time to last unformed stool was 67.5 h after rifamycin SV and 65.5 h after rifaximin. Conclusions: The efficacy of the new tablets was not significantly different from that of rifaximin administered 4 times a day for 3 days. The treatments did not differ in rate or frequency of therapeutic success. Isolates of Campylobacter jejuni and lari, Escherichia coli, Anaerobiospirillum, Salmonella enteritidis and Shigella flexneri found at pre-treatment were not retrievable after rifamycin SV.
Keywords: Infectious diarrhoea, MMX, non-absorbable antibiotics, rifamycin SV, rifaximin.
Anti-Infective Agents
Title:Efficacy of the Treatment of Infectious Diarrhoea with Non-Absorbable Rifamycin SV Formulated as MMX Modified Release Tablet vs. Rifaximin
Volume: 11 Issue: 2
Author(s): A.F.D. Di Stefano, D. Binelli, W. Labuschagne, M. Mojapelo, E. van der Walt, S. Patel and L. Moro
Affiliation:
Keywords: Infectious diarrhoea, MMX, non-absorbable antibiotics, rifamycin SV, rifaximin.
Abstract: Background: The non absorbable antibiotic rifamycin SV newly formulated as modified colonic release MMX® tablets was preliminarily investigated. Methods: In a multi-centre, double-blind, double-dummy, randomised, parallelgroup study, efficacy and safety of the 200 mg tablets were investigated vs. rifaximin 200 mg tablets in infectious diarrhoea. Results: 22 rifamycin SV recipients (47.8%) were successes, whilst 24 (52.5%) discontinued. In the reference group 27 (50.9%) were successes, whilst 26 (49.1%) discontinued. The median time to last unformed stool was 67.5 h after rifamycin SV and 65.5 h after rifaximin. Conclusions: The efficacy of the new tablets was not significantly different from that of rifaximin administered 4 times a day for 3 days. The treatments did not differ in rate or frequency of therapeutic success. Isolates of Campylobacter jejuni and lari, Escherichia coli, Anaerobiospirillum, Salmonella enteritidis and Shigella flexneri found at pre-treatment were not retrievable after rifamycin SV.
Export Options
About this article
Cite this article as:
Stefano A.F.D. Di, Binelli D., Labuschagne W., Mojapelo M., Walt E. van der, Patel S. and Moro L., Efficacy of the Treatment of Infectious Diarrhoea with Non-Absorbable Rifamycin SV Formulated as MMX Modified Release Tablet vs. Rifaximin, Anti-Infective Agents 2013; 11 (2) . https://dx.doi.org/10.2174/2211352511311020013
DOI https://dx.doi.org/10.2174/2211352511311020013 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pathological Gambling: Neuropsychopharmacology and Treatment
Current Psychopharmacology Pregnancy and Sleep Apnea
Current Respiratory Medicine Reviews Intravenous Immunoglobulin Preparations and Autoimmune Disorders: Mechanisms of Action
Current Pharmaceutical Biotechnology Back Pain in the Young: A Review of Studies Conducted Among School Children and University Students
Current Pediatric Reviews A Perspective on Monoamine Oxidase Enzyme as Drug Target: Challenges and Opportunities
Current Drug Targets New Developments in Therapeutic Agents for Legionnaires Disease
Anti-Infective Agents in Medicinal Chemistry Subject Index To Volume 2
Current Rheumatology Reviews Posterior Reversible Encephalopathy Syndrome with Atypical Presentation: A Pictorial Review on MR Imaging Features
Current Medical Imaging Forodesine (BCX-1777, Immucillin H) - A New Purine Nucleoside Analogue: Mechanism of Action and Potential Clinical Application
Mini-Reviews in Medicinal Chemistry Management of a Mental Health Crisis in an International High School Exchange Student: A Case Study
Adolescent Psychiatry May Patients with Alcohol Liver Disease Benefit from Herbal Medicines?
Reviews on Recent Clinical Trials The Effects of Placental Corticotrophin Releasing Hormone on the Physiology and Psychology of the Pregnant Woman
Current Women`s Health Reviews Brain Tumor Causes, Symptoms, Diagnosis and Radiotherapy Treatment
Current Medical Imaging Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Anti-HIV Drug Distribution to the Central Nervous System
Current Pharmaceutical Design Enzalutamide: A Novel Anti-androgen with Prolonged Survival Rate in CRPC Patients
Mini-Reviews in Medicinal Chemistry D-Cycloserine as an Augmentation Strategy for Cognitive Behavioral Therapy for Anxiety Disorders: An Update
Current Pharmaceutical Design Expectancy and the Treatment of Depression: A Review of Experimental Methodology and Effects on Patient Outcome
Current Psychiatry Reviews Physical Therapy Modalities in Management of Fibromyalgia
Current Pharmaceutical Design Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD): A Systematic Review of Recent Data
Current Psychopharmacology